Publications by authors named "Shanti Werther"
Objective: To explore long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP) trial and enrolled in the placebo-controlled 3-year long-term extension (LTE) study (ClinicalTrials.gov identifier: NCT02794285).
Methods: In the blinded LTE study, patients continued anifrolumab 300 mg, switched from anifrolumab 150 mg to 300 mg, or were re-randomized from placebo to receive either anifrolumab 300 mg or to continue placebo, administered every 4 weeks.
Aims: To compare the efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) administered three times daily (TID) vs. twice daily (BID), plus metformin, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin ± 1 oral antidiabetic drug (OAD).
Methods: Randomised, multinational, open-label, treat-to-target trial.
Article Synopsis
- A 32-week trial compared the effectiveness and safety of biphasic insulin aspart 30 (BIAsp 30) versus a basal-bolus insulin regimen in adults with type 2 diabetes who were also taking metformin and sulfonylurea.
- Results showed that the BIAsp 30 group had a slightly higher mean change in HbA after 32 weeks, but the proportion of patients achieving HbA below 7.0% was lower than in the basal-bolus group. Overall, BIAsp 30 had fewer nocturnal hypoglycemic events.
- The study concluded that while both treatments improved glycemic control, BIAsp 30 resulted in a